Please login to the form below

Not currently logged in
Email:
Password:

Farxiga

This page shows the latest Farxiga news and features for those working in and with pharma, biotech and healthcare.

AZ expects return to growth this year after 2017 decline

AZ expects return to growth this year after 2017 decline

The contribution of these drugs as well as blockbuster sales for antiplatelet therapy Brilinta (ticagrelor) and diabetes drug Farxiga (dapagliflozin) allowed AZ to boost operating profit by 2% to $6.86bn

Latest news

More from news
Approximately 4 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    and was the pharma company with the most approvals from the US FDA with four last year, including the diabetes drug Farxiga (dapagliflozin) and Lynparza (olaparib) for ovarian cancer.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics